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resumo 
 
 
Este relatório descreve as atividades que desenvolvi e as aprendizagens que 
adquiri durante o meu estágio curricular, enquanto Coordenadora de 
Investigação Clínica na Blueclinical – Investigação e Desenvolvimento em 
Saúde, Lda. 
 
O estágio curricular foi realizado no âmbito do segundo ano do Mestrado de 
Biomedicina Farmacêutica da Universidade de Aveiro. 
 
A principal atividade desenvolvida foi a coordenação de ensaios clínicos no 
Centro Hospitalar Vila Nova de Gaia/Espinho, desde as fases mais iniciais do 
seu desenvolvimento – questionários de exequibilidade – até às fases mais 
tardias – visita de fecho. No entanto, pertencer a uma empresa ainda em 
processo de criação foi uma mais-valia pela pluralidade das tarefas efetuadas, 
incluindo tarefas relacionadas com gestão, criação do sistema de gestão de 
qualidade, entre outras. 
 
Durante o estágio foi-me possível tomar conhecimento das dificuldades 
encontradas durante a criação e implementação de um Gabinete de 
Investigação Clínica e também aperceber-me de algumas diferenças entre o 
mundo académico e o mundo profissional. 
 
Para além da descrição das atividades desenvolvidas e dos objetivos que me 
propôs a atingir, este relatório tenta contextualizar o estágio na estrutura da 
Blueclinical e no estado de arte da investigação clinica. É também apresentada        
uma análise crítica dos pontos fortes, pontos fracos, dificuldades e 
oportunidades encontrados durante o estágio. 
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Abstract 
 
This report describes the activities I have developed and the knowledge I have 
acquired during my curricular training as Clinical Research Coordinator at 
Blueclinical – Investigação e Desenvolvimento em Saúde, Ltd. 
 
The curricular training is part of the second year of the Master’s Degree 
program in Pharmaceutical Biomedicine University of Aveiro. 
 
The main activity developed was the clinical trials coordination at Hospitalar 
Center Vila Nova de Gaia/Espinho, since the earliest phases – feasibilities – 
until latest phases – close-out visit. Nevertheless being part of a recent 
company, still in creation phase, was a positive aspect as it allowed me to 
perform a large variety of tasks, including management, creation of the quality 
system, among others. 
 
During the internship I was able to acknowledge the difficulties faced while 
creating and implementing a clinical research office, as well as acknowledge 
some differences between the academic environment and the professional 
environment. 
 
Besides the description of the activities developed and the objectives, this 
reports intents to contextualize the internship in Blueclinical’s structure and in 
clinical research state of art. It is also presented a critical analysis of the 
strengths, weakness, opportunities and threats faced during the curricular 
training.  
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 1. INTRODUCTION 
The present work intends to report the activities developed and experience acquired during 
a ten months curricular internship at Blueclinical – Investigação e Desenvolvimento em 
Saúde, Lda (hereinafter “Blueclinical”). The internship took place during the second year 
of the Master’s Degree in Pharmaceutical Medicine at the University of Aveiro, beginning 
in July 2013 and ending in April 2014. 
During my internship, my primary activity was the coordination of clinical research at a 
study centre – Hospital Centre of Vila Nova de Gaia/Espinho1 (CHVNG/E). Clinical 
research coordination is a multidisciplinary job, where the contact with other people is 
crucial to accomplish tasks successfully. My core activity was developed in the context of 
Blueclinical Clinical Research Partnership (CRP), which is one of the Blueclinical’s main 
functional areas. Besides CRP the other areas are Research & Development (R&D) and 
Phase I (PHI). 
My internship can be split in two different phases, the first one between July 2013 and 
mid-January 2014, when I was based at CHVNG/E as Clinical Research Coordinator 
Trainee, and the second one between mid-January 2014 and April 2014. The second phase 
started when I left CHVNG/E and went to Hospital Centre of Tondela-Viseu (CHTV). Due 
to external factors I did not stay a long period at the hospital, so during the last few months 
of my curricular training I developed my activities at different study centres and also at the 
Blueclinical back office. 
In this report I describe what I have done and the professional experience I have gained, 
regarding the context of the company activities and the clinical trials area. To allow this 
contextualization, the present chapter provides an overview of Blueclinical history and 
organization. After that, my training objectives are presented, both the ones related with 
the company and the general ones.  
The remaining report will be organized as follow: 2. Clinical Research State of Art; 3. On 
the job training; 4. Discussion; 5. Conclusion. 
1 A Hospital Centre, according with the Portuguese national law is considered a collective person, with financial and administrative 
autonomy. It gathers together different and autonomous hospitals but their coordination and/or Administration is common (39). 
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Chapter 2 provides the state of art of clinical research, describing what clinical trials and 
observational studies are, the main differences between them and the applicable legislation. 
The changes that are occurring nowadays are also described. 
In the third chapter, the activities I have performed CHVNG/E, Hospital Centre of Baixo 
Vouga (CHBV), CHTV, Hospital Centre of Cova da Beira (CHCB) and Blueclinical’s 
back office are described.  
In chapter 4, I discuss how the internship contributed to the improvement of my skills, 
what were the main challenges I have faced and how my academic background has 
influenced my daily job. Both the positive and negative issues of my internship are 
presented as well as the way I have faced them. Furthermore the achievement or failure to 
reach the objectives I have defined in subchapter 1.2 is debated. 
The last chapter is a conclusion of the report where I sum up all the relevant issues of my 
curricular training, such as the experience acquired, major problems and successes.  
1.1. BLUECLINICAL – INVESTIGAÇÃO E DESENVOLVIMENTO EM SAÚDE, LDA 
Blueclinical – Investigação e Desenvolvimento em Saúde, Lda. (1) is a company created in 
2012. Blueclinical’s competences cover every single phase of the research and 
development of new drugs – from bench to bedside.  
As previously referred, Blueclinical is organized in three main functional areas: R&D, PHI 
and CRP. The company logo (Figure 1) is a representation of those three areas, being each 
area represented by a different tone of blue. 
 
Figure 1 – Blueclinical Logo. The three functional areas are represented on the rectangle above the company 
name. Reproduced from Blueclinical’s website (1). 
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 Blueclinical R&D  provides support to institutions and companies in the different stages of 
the research and development of new products (drugs, medical devices and other health 
products) process (1,2). The mission of R&D is to empower translational research in 
Portugal, being a contribution to the transformation of basic research into new therapeutic 
and diagnostic products and services (2,3). 
Blueclinical PHI is a centre to conceive, organize and develop phase I clinical trials, with 
different medicines (1). PHI headquarters are at Hospital da Prelada, Oporto, and have 29 
beds available for clinical trials on healthy volunteers (phase I studies) or selected patients 
populations (early proof-of-concept studies) (4,5). 
 
Figure 2 – Blueclinical CRP network, on April 2014. Logos of the institutions and of the offices created at 
each institution. Reproduced from Blueclinical’s website (7). 
Blueclinical CRP provides organizational support to clinical investigation on health care 
institutions (1). According to the company website, its mission is to “support the activity of 
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clinical research centres, promoting their growth, efficiency gain and achieving a 
reputation for excellence in clinical research” either promoted by pharmaceutical/medical 
devices industry or promoted by institutional investigators (6). At this moment, thirteen 
different institutions are gathered at CRP network (Figure 2). Belonging to the CRP 
network means that a clinical research office will be set up at the institution, counting with 
at least one Blueclinical collaborator at the office. The first office was created on CHCB in 
January 2013, followed by the office on CHVNG/E in April 2013. The newest centre of 
the network is placed at Hospital Centre of Trás-os-Montes e Alto Douro. 
This network allows sharing the best practices in clinical investigation, the harmonization 
of procedures, and provides institutions enough size to be advertised outside Portugal. 
Blueclinical supports the qualification and European Certification of investigation teams 
(6). 
 
Figure 3 – Blueclinical Organogram. Areas where I developed my internship activities are highlighted in 
green. Adapted from Blueclinical’s Quality Manual (8). 
(BD – Business Development; CD – Clinical Director; CDM – Clinical Data Management; CDP – Clinical Data 
Programming; COD – Clinical Operations Director; CRC – Clinical Research Coordinator; CRM – Clinical Research 
Manager; CRP – Clinical Research Partnership; CTA – Clinical Trial Assistants; DMS – Data Management and Statistics; 
F&A – Finances and Accounting; HR – Human Resources; IT – Information Technology; LA – Legal Affairs; LT – 
Laboratory Technicians; MP – Managing Partners; MWR – Medical Writing and Reporting; OHS – Occupational Health 
and Safety; PH – Research Pharmacy; PHM – Pharmacometrics; PM – Project Management; QA – Quality Assurance; 
QAM – Quality Assurance Manager; R&D – Research and Development; RN – Research Nurses; RP – Research 
Physicians; SF – Support Functions; SRM – Safety Risk Management; STA – Statistics) 
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 Nowadays Blueclinical counts with, approximately, forty-five internal collaborators, 
twenty-two of them allocated to CRP. The organization of Blueclinical is described in 
Figure 3.  
During my training, I had closer contact with the two clinical research coordinators (CRC) 
of CHVNG/E, the Clinical Research Manager (CRM) of CHVNG/E, CHTV and Hospital 
Centre of Alto Ave and with the Clinical Operations Director (COD).  
1.2. TRAINING OBJECTIVES 
During the first year of my master degree I decided that I would do a curricular training. At 
the time, I established some objectives that I intended to achieve independently of the 
company where I was going to be. Those objectives are:  
− Improve my communication skills, both written and spoken; 
− Improve my autonomy, self-confidence, organization, team group working skills, 
sense of responsibility;  
− Use the knowledge acquired both in my degree and master degree; 
− Develop my professional network. 
After knowing I was going to Blueclinical and after understanding the CRP objectives and 
mission, as well as my job role, I set the following objectives: 
− Be acquainted with the steps and procedures to implement a Clinical Investigation 
Centre at an Hospital;  
− Know how to plan, conduct and coordinate a clinical trial/observational study from 
feasibility to close-out visit, regarding the applicable legislation, patients and 
monitoring visits preparation, CRF (Case Report Form) filling, query resolution, 
etc.; 
− Learn how to review and improve financial agreements; 
− Learn how to create and maintain a quality system, as well as prepare the centre to 
inspections or audits; 
Page 5 of 47 
 
− Create a relationship with physicians and other clinical trial personnel, in order to 
motivate themselves and to augment their compliance with GCP’s (Good Clinical 
Practices); 
− Develop a balanced relationship with Blueclinical’s collaborators both to maintain 
a positive working environment and to help each other on daily activities; 
− Contact with patients and try to make their participation on clinical trials easier; 
− Contribute both for the development of Blueclinical and of other institutions where 
I have been based regarding Clinical investigation; 
− Acquire basic knowledge in clinical trials monitoring tasks. 
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 2. CLINICAL RESEARCH STATE OF ART 
The main objective of this chapter is to provide the theoretical basis of this report, 
regarding what clinical research, clinical trials phases, and applicable legislation are. The 
chapter is divided in three sub chapters, the first one about clinical trials, the second one 
about observational studies and the third one about legislation. 
2.1. CLINICAL TRIALS 
According to the directive 2001/20/EC (9), clinical trials are “any investigation in human 
subjects intended to discover or verify the clinical, pharmacological and/or other 
pharmacodynamic effects of one or more investigational medicinal product(s), and/or to 
identify any adverse reactions to one or more investigational medicinal product(s) and/or to 
study absorption, distribution, metabolism and excretion of one or more investigational 
medicinal product(s) with the object of ascertaining its (their) safety and/or efficacy” (9). 
Traditionally the R&D model is described as a four sequential phases’ process, based on 
“trial and error". In practice, those phases are not sequential, as one type of trial could 
occur at different time points of the drug development process, or studies from different 
phases could take place at the same time. A classification system based on the studies 
objectives was developed (10). Each term of this classification system corresponds to one 
phase as described below: 
− Phase I - or Human Pharmacology Studies. These studies are designed in order to 
assess tolerance, determine pharmacokinetic and pharmacodynamic profiles, 
describe the drug metabolism and interactions and identify the maximum tolerated 
dose. Usually these studies are performed on healthy volunteers (10). 
− Phase II - or Therapeutic Exploratory Studies. These studies are developed on the 
target patient population with the intent of estimate the dosage for following 
Studies, and define the preliminary tolerability/safety profile in patients (10). 
− Phase III - or Therapeutic Confirmatory Studies. These studies are performed on 
larger patient populations, being the selection criteria as similar as possible to the 
daily routine conditions. Their objective is to confirm the therapeutic effectiveness 
and set the conditions of usage in regular medical routine (10). 
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− Phase IV – or Therapeutic Use. These are usually post-marketing approval studies, 
designed to provide further information on the therapeutic effectiveness in real life 
conditions. They also assess the value of the new medicine compared with the 
existing alternatives (10). 
This R&D model is becoming unsustainable for the pharmaceutical industry as it is very 
expensive and has very high failure rates (Figure 4 and Figure 5). The problems of this 
R&D model are: 
− Too slow – easily a compound takes 15 years to be placed in market. Patents are 20 
years long, so companies only have 5 years to achieve profits (11,12). 
− Too expensive – the total cost of bringing a new drug to market could reach more 
than 1000 million US dollars, a value that largely increased in the past few years 
(11,12). 
−  High failure rates – in average for each drug that launches market, approximately 
24 compounds have to initiate the preclinical phase. The lowest successful rates 
happen between phase 2 and phase 3, the most expensive phases (11,12). 
− Too inefficient – in spite of the increase of costs, which means an increase in 
investments, the number of drugs that are placed in market is decreasing (11,12) 
 
Figure 4 – New Medical Entities (NME) vs success rates. Data from the 14 large pharmaceutical 
companies’ regarding the approval of one NME. Reproduced from 13.  
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Figure 5 – Pharma productivity between 2005 and 2010. R&D costs versus NMEs approved, regarding 9 
of the largest pharmaceutical companies. Reproduced from 13. 
The traditional R&D model no longer answers the necessities of pharmaceutical industry. 
Looking for a change, two different programs were developed – IMI (Innovative 
Medicines Initiative) and CPI (Critical Path Initiative). 
IMI is a unique pan-European public and private sector collaboration between large and 
small biopharmaceutical and healthcare companies, regulators, academia and patients (14). 
CPI is United States Food and Drugs Administration’s (U.S. FDA) national strategy for 
transforming the way U.S. FDA regulated medical products are developed, evaluated, and 
manufactured (15). 
These two initiatives pointed out a new R&D strategy that is focused in the study of the 
pathophysiology allowing the development of better compounds, using better targets and 
new biomarkers (Figure 6).  
The use of bioinformatics, adaptive trial designs, historical control data, together with 
better targets and new biomarkers, allows that the development of new compounds fail at 
an earlier point, before the expensive stages (phase II and III trials) (16). 
The new R&D strategy is first of all based on a better knowledge of the pathophysiology 
and epidemiology of diseases. This knowledge will be achieved prior to the initiation of 
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the expensive development phases. It will be necessary to know the diseases subtypes and 
their nature and incidences; physiological mechanisms that could be the target of 
treatments; biomarkers that can differentiate patients groups, personalizing therapeutics 
(11).  
 
Figure 6 – The new R&D model. Comparison between the traditional and the new R&D models. Adapted 
from 11. 
Only after there is confidence in mechanism, the R&D process will proceed to other step, 
which is the molecule development (Figure 6). This step regards the performance of highly 
targeted clinical studies, supported by simulation, modelling and other technologies. The 
objective is to achieve confidence in safety and in efficacy. When there is enough data to 
support the drug use in a certain target population, submission to the regulatory authorities 
can be made. This submission will be limited to that target population – limited launch 
(Figure 6). After obtaining the first launch authorization, the drug will enter a development 
loop to extend the marketing authorization to other populations or other indications – 
limited launch with live licence. This new approach will make the R&D process more 
efficient, effective and less expensive. Patients will be able to have access to new 
medicines at an earlier stage (11,12). 
Earlier this year, the European Medicines Agency (EMA) launched an adaptive licencing 
pilot project whose objective is to faster the access of patients to new medicines. 
Companies who will take part of this project will have their medicines authorized at an 
earlier stage of the drug development although its marketing is restricted to controlled 
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 patient populations. As further information is gathered, the marketing authorization could 
be updated, in order to expand the use of the medicinal product to larger groups of patients 
(17). 
2.2. OBSERVATIONAL STUDIES 
An observational study is a study that searches out data about people that per standard of 
care take a specific drug, or activity or lifestyle. It is also called non interventional study as 
no procedure is done outside the daily medical routine (18). Observational studies tend to 
be less complex compared with clinical trials.  
Depending on the observational studies design, they can be classified as: 
− Case-Control – study that starts with the effect (disease) and goes straight to the 
cause; 
− Cohort – it is similar to a clinical trial because it starts with a cause and directs to 
the effect. The groups are formed by observation of exposure or no exposure on 
real life; 
− Cross-Sectional – in these studies the cause and the effect are detected 
simultaneously (18). 
Observational studies can be conducted at a point in time or be longitudinal ones. In 
longitudinal studies multiple measurements are performed during a period of time. It is 
possible to assess changes, as a unique group of population is studied (18).  
These studies can also be prospective or retrospective. Retrospective studies use already 
archived data, for example by patient files research. Prospective studies are characterized 
by the enrolment of subjects in advance and following them through a defined period of 
time (18). 
Observational studies usually are performed as post-market authorization studies, in order 
to collect additional information on safety and efficacy (18). 
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2.3. LEGISLATION 
Clinical research is a highly legislated area. Looking backwards to the history of 
regulations, in 1848 the United States of America took the first regulatory action regarding 
drugs. The Drug Importation Act was created forbidding the import of adulterated drugs 
(19). The first attempt to legislate medicines and food happened in 1906 with the Pure 
Food and Drugs Act, created by President Roosevelt.  
In 1947 the Nuremberg Code was established as a consequence of “The Nazi Doctors 
Trials” (19). Nuremberg Code was developed by four American judges involved in the 
judgement of the Nazis doctors. It is a ten-point document with the basic principles of 
ethical behaviour while conducting experiences in human. This code is still followed 
today. 
The Declaration of Helsinki was established in 1964. Although it repeats the Nuremberg 
code requirements, it praises the use of written consent and defines as mandatory the prior 
review and approval of the protocol by an Institutional Review Board. Declaration of 
Helsinki is morally binding for physicians, and whenever its statements provide higher 
protection for subjects, the declaration overrides the national or local laws and regulations. 
Periodically this document is reviewed and new versions are published (19). 
The International Conference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use (ICH) was formed in 1990 in order to 
achieve a unified standard for the European Union (EU), Japan and United Stated, which 
allows the mutual acceptance of clinical data, by each party regulatory authorities (19). 
ICH provides guidelines concerning Institutional Review Boards and Institutional Ethics 
Committees; investigator; sponsor; protocol and protocol amendments; investigator 
brochure and other essential documents. Regarding clinical trials, ICH Good Clinical 
Practices (ICH-GCP) (20) are probably the most important guidelines. Some of the ICH-
GCP principles are: 
− Risks and benefits should be carefully assessed; 
− The rights, safety and wellbeing of trial subjects are the most important; 
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 − Trial should be supported on the available information about the investigational 
product; 
− All medical care of and decisions about study subjects should be responsibility of a 
qualified physician; 
− All subjects that enter a trial should provide their consent in a freely and informed 
manner; 
− Good manufacture practices should be followed during the manufacture, handle 
and storage of the investigational product. 
Later, the co-existence of ICH-GCP and country local legislation became a problem when 
implementing a multicentre clinical trial. EU, in 2001, published a directive on clinical 
trials (9) that was transposed to the state members’ national law prior to 1st May 2004. The 
objective of the directive was the harmonization of laws, regulation and procedures 
through the Member States. 
On 2005 a new directive (21) with principles and detailed guidelines for good clinical 
practice was launched. It regards not only the investigational medicinal products for human 
use, but also the requirements for authorization of the manufacturing or importation of the 
investigational products. 
Due to the increase of the costs associated with the conduction of clinical trials and the 
decrease in new clinical trials, EU Members States considered that it was necessary to act, 
so they presented a proposal for a regulation (22). This year, the Regulation (23) was 
approved by the European Parliament and by the Council.  
Comparing the new regulation with the 2001 (9) and 2005 (21) directives, several changes 
could be noticed. The first main alteration is that the new regulation has legal force 
throughout every Member State, without need of national implementation (9,23). 
Alterations to the authorization procedure have been done. The entire procedure is now 
regulated in a more detailed way.  The procedure can be summarized as follows: 
submission of an application dossier to the chosen Member States, proposing the reporting 
one; the reporting Member State has 6 days to inform the sponsor about:  1) whether they 
accept or not being the reporting Member State, 2) whether the clinical trial fulfil or not the 
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scope of the regulation, 3) whether the application is complete or not and 4) whether the 
clinical trial is or not a low intervention clinical trial (only when requested by the sponsor). 
When reporting member gives no information to the sponsor, all the previous items are 
applied. If information is incomplete or any other problem is noticed, the sponsor has 6 
days to comment and/or complete the application. If sponsor does not provide an answer 
within those 6 days, the authorization procedure is withdrawn. If there is no notification by 
the reporting Member State within 3 days after the submission of sponsor’s answer, the 
application should be considered complete. All the communications labelled before will be 
performed through EU portal (23).  
Chapter 3 substitutes article 10(a) from directive 2001/20/EC, on the explanation of the 
authorisation procedure for a substantial modification of a clinical trial. This explanation is 
made in much more detail than before. Information provided in chapter 4 has no equivalent 
information in the directive. Jointly with annex 1, this chapter defines rules on the content 
of the application dossier. 
Chapter 7 is about safety reporting. The report of adverse events (AE) follows the practice 
set up in directive 2001/20/EC. The report of serious adverse events (SAE) follows the 
same practice, being reported to the sponsor. Only the unexpected serious adverse 
reactions are reported to the EMA, by an electronic database set up and maintained by the 
Agency. The Database must include the safety reports. The sponsor must report without 
delay the unexpected SAE occurred in its clinical trial. The timeframe of the report is 
determined by the severity of the reaction, and it could be submitted an incomplete report, 
followed by a complete report as soon as possible. If there is no possibility of electronic 
report, the event should be reported to the Member State, where the event happened. The 
Member State has the obligation of doing the electronic report. Besides these, this chapter 
defines rules about annual reporting to Member States and to marketing authorization 
holder, and assessment by Member States (23). 
Directive 2001/20/EC (9) determines that all clinical trials must have an obligatory 
insurance/indemnity (9). In Chapter 12 the regulation (23) modifies this situation, setting 
that the insurance/indemnity is dependent of the risk of participating in the trial in 
comparison to the risk induced by normal clinical practice treatment (23). 
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 Unlike in the directive, several annexes are present in the regulation. They contain more 
detailed information on some aspects defined in the regulation, such as the content of the 
application dossier and the safety reporting. 
Although the new Regulation has already been publicized in the Official Journal of the 
European Union, it will be applied no earlier than the 28th May 2016 (23). 
Regarding the Portuguese regulatory framework, two law-decrees were published on 1994 
(24) and 1995 (25). Those were the first Portuguese laws on clinical trials. The Directive 
2001/20/EC (9) was transposed to the law 46/2004 (26). This law established the 
obligation of favourable opinion from the Portuguese ethics committee – (Comissão de 
Ética para a Investigação Clínica - CEIC) and authorization from the Portuguese regulatory 
authority (Autoridade Nacional do Medicamento e Produtos de Saude, I.P. – INFARMED) 
and from Portuguese data protection commission (Comissão Nacional de Protecção de 
Dados).  
The Directive 2005/28/EC (21) was transposed to the law-decree 102/2007 (27). Besides 
the information about good clinical practices, it has information on essential documents 
archiving and on inspections. 
Personal data protection is regulated by law 67/98 (28), being the deliberation 333/2007 
(29) exclusively about protection of personal data on clinical trials and the deliberation 
227/2007 (30) about personal data protection on non-interventional studies. 
The regulatory framework in Portugal is presently suffering a change, as the new law on 
clinical research (31) was approved on the 3rd April 2014, and will enter into force during 
June 2014. This new law revokes the law 46/2004 (26). 
This new law not only regards the authorization and conduction of clinical trials but also 
their divulgation. The CEIC role is clarified as well as more responsibilities are assigned to 
the local ethics committee. It creates a national registry of clinical research (Registo 
Nacional de Investigação Clínica). The objective of the national registry is the increase of 
the interaction between all clinical research stakeholders (32). 
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Figure 7 – Clinical trials in Portugal between 2006 and 2013. Approval times, number of submissions to 
INFARMED and approvals from the national authority. Between 2006 and 2013 the number of approved 
clinical trials decreased approximately 21%. Adapted from INFARMED (33). 
The new law is seen as an opportunity to change the present situation of clinical trial. Since 
2006 there is a considerable decrease in the number of clinical trials submitted to the 
Portuguese regulatory authorities (Figure 7). In 2011 just 88 studies were approved (33). 
Only if Portugal becomes more competitive and attractive to the pharmaceutical companies 
this situation could be changed (34).  
 
 
 
 
 
Figure 8 – Number of new patients recruited, in Portugal, per year, between 2009 and 2012. Excepting 
in 2011, the number of recruited patients has been diminishing. Reproduced from 35. 
Patients’ recruitment is a critical issue, as between 2007 and 2011 only 70% of the initial 
number of planned patients were enrolled (34). The low patient recruitment (Figure 8) 
could be a consequence of the reduced number of centers per study in our country, and 
also a consequence of the low recruitment capacity of each site (34). 
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 The negative scenario of clinical trials do not only affect the reputation of Portuguese sites 
near the pharmaceutical industry, but also cause a negative impact on the financial system. 
In the pharmaceutical sector, every euro that is invested results in 1,98 euros, so creating 
competitive conditions to the conduction of clinical trials should be imperative (34). 
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 3. ON THE JOB TRAINING 
My collaboration with Blueclinical started on April 2013, when I had an interview with 
Cristina Lopes, the COD, and I was accepted to do my curricular internship there, as CRC. 
On 8th May 2013, I attended a training session where I met other Blueclinical’s 
collaborators. Nevertheless my internship started on the 3rd July 2013. Since that day, until 
mid-January 2014 I was a full time study coordinator at CHVNG/E.  
By the end of 2013 Blueclinical’s administration board proposed me to move to Viseu to 
coordinate the local clinical research office. The CRP team was suffering changes in order 
to maximize the efficiency of the staff and fulfil the necessities of every hospital. As I have 
accepted the challenge, I had two weeks to finish my job at CHVNG/E and then two weeks 
to observe a different work strategy at CHBV. After that, I had to be ready to start working 
at CHTV in the first week of February 2014. As the administration board of the hospital 
raised issues about the collaboration with Blueclinical, I only spent there one month. The 
month of March was spent working home based at Viseu. During that month, I went to 
CHCB a few days to work there. In the beginning of April I definitively left Viseu and 
moved to the Blueclinical’s back office (Figure 9). 
 
 
 
 
 
 
 
Figure 9 – Chronology of my internship – The hospitals where I was based are displayed as well as the 
training sessions. 
In order to facilitate the description of the activities performed, this chapter is organized as 
follows: 3.1. – CHVNG/E; 3.2. – Other Activities Developed; 3.3. – Training. The first 
subchapter is divided according with the tasks I have done at CHVNG/E. Subchapter 3.2 
Page 19 of 47 
 
describes all the activities performed at CHBV, CHTV, CHCB and at back office. The last 
subchapter contains a description of the training sessions I attended, both provided by 
Blueclinical and by external entities. 
3.1. HOSPITAL CENTRE OF VILA NOVA DE GAIA/ESPINHO 
CHVNG/E was created by the law-decree 50-A/2007, of 28th February 2007, gathering 
together Hospital Centre of Vila Nova de Gaia and the Hospital Nossa Senhora da Ajuda, 
from Espinho (35). CHVNG/E is divided into three units, being unit 1 in Monte da 
Virgem, unit 2 in the centre of Vila Nova de Gaia city and unit 3 in the centre of Espinho 
city. 
Assuring high quality and efficient health care services is part of the hospital mission, as 
well as having highly motivated and satisfied professionals. The administration board also 
defined training, investigation and scientific development as part of the hospital mission 
(36). It is estimated that the population under the hospital area is about 700 thousands 
inhabitants (37). 
Resulting of a collaboration agreement between Blueclinical and CHVNG/E, the Clinical 
Research Office (Gabinete de Investigação Clínica – GIC) was created with the objective 
of supporting clinical research from industry and from local investigators. The agreement 
was signed on 1st April 2013, and the first Blueclinical collaborator at the hospital started 
working on 16th April 2013. However, only a few months later, in July 2013, the physical 
installations were available. 
GIC organizational structure is divided into three parts: coordination, Supporting Office to 
Clinical Research Office (Gabinete de Apoio ao Gabinete de Investigação Clínica 
(GAGIC)) and associate clinical investigators (Figure 10). GIC’s coordinator is Doctor 
Hugo Tavares, a paediatrician at CHVNG/E unit 2 and one of the external experts 
nominated by INFARMED at the Paediatric Committee of the EMA. GAGIC is formed by 
Blueclinical’s collaborators based at CHVNG/E. During my training, Sónia Correia was 
the Clinical Research Manager and myself, Daniela Cabeleira and Rita Espanhol (since 
September 2013) were the CRCs. Associated clinical investigators are the medical staff 
that desire to associate themselves with GIC and perform, successfully, the PharmaTrain 
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 Clinical Investigator Certification, a training provided by Blueclinical. It regards training 
in clinical research, GCPs and clinical investigation quality system. 
 
Figure 10 – GIC organizational structure. Adapted from Blueclinical and CHVNG/E collaboration 
agreement (38). 
As my training started right after GIC creation, I performed several activities related with 
GIC implementation and its divulgation near the medical staff.  
One of those activities was the presentation meeting to all the medical directors of the 
hospital that took place on 10th July. At this meeting, Blueclinical was represented by its 
Managing Partners Doctor Luis Almeida and Doctor Sergio Simões, the COD Cristina 
Lopes, and some colleagues based at other hospitals from the network. The CHVNG/E 
administration board president made an introductory speech, focusing the reasons why the 
hospital needed a Clinical Research Office. Doctor Luis Almeida, as the Blueclinical 
owner, also made a speech, presenting the current situation of clinical research in Portugal 
and explaining why the present scarcity of clinical trials could and should be seen as an 
opportunity to do more and to do better. The Hospital Clinical Director made his 
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communication referring how Blueclinical’s projects matches the hospital strategic plan. 
He clarified that the main objectives of the partnership were achieving conditions to 
maximize clinical research at the hospital and contributing to the development of medical 
sciences. Afterwards, the GIC coordinator made a brief presentation of the GIC structure, 
competences, and the following steps to be performed by the office staff. 
After this meeting, and by GIC coordinator initiative, a sequence of meetings with every 
clinical and non-clinical services took place. Those meetings intended not only to 
introduce GIC to CHVNG/E professionals on a more personal way but also to learn about 
the history of clinical research at the hospital and to know what are the expectations of the 
hospital staff regarding GIC collaboration. 
An effort was made to provide suitable material to the office, such as computers, mobile 
phone, printer and more chairs and desks. For electronic material, written requests 
addressed to administration board were made, while chairs and secretaries were rescued 
from the old material repository. 
The activities of GIC implementation and divulgation were a small part of the activities I 
have developed. All the activities I have performed were done in close collaboration with 
my office colleagues. I had the opportunity to participate in the following tasks: 
• Templates development; 
• Feasibilities 
• Investigators meeting 
• Initiation meetings 
• Patients recruitment 
• Patients visits 
• Monitoring visits 
• Other administrative tasks 
During the time I spent at CHVNG/E, I coordinated three clinical trials on lung cancer, one 
clinical trial on diabetes and one observational study on psoriasis. On the lung cancer trials, 
I was involved on the randomization of two patients, following a total of 5 patients, and I 
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 had one screening failure. On the diabetes clinical trial I followed 4 patients, and on the 
psoriasis study I was involved on the inclusion of one patient. 
3.1.1. Templates development 
The idea when creating templates is providing tools that help our work as well as 
harmonize the documents used. As GIC was recently created, there were only a few 
templates. Templates development is an ongoing task, as only with the use of the 
documents it is possible to evaluate their usability and utility. Frequently it is necessary to 
develop new ones or update the existing ones. There are templates for external use such as 
Curricula Vitae (CV), verification list for clinical trials and clinical/observational studies, 
submission letter and templates for internal use as tables for kits control, tables for listing 
concomitant medication and SAEs and AEs, tables to control participants expenses, tables 
to calculate exams or visits date, internal mail protocol, calendars, financial evaluation 
summary. 
I have adapted the Blueclinical’s CV template, adding the hospital and the GIC logos to the 
document, and indicating the hospital address. Besides the personal information, this CV 
requests information related with clinical research experience and relevant training 
courses, as these topics have major importance to sponsors. The template is supposed to be 
used by everyone that is part of GIC. Its divulgation was done by e-mail, requesting the 
receiver to fill in the document, print, sign and sent it back to the office. Under special 
circumstances, for example when there is a lack on language skills (the template is written 
in English), the template is filled in by GAGIC. I created a dossier with all CVs signed and 
dated, as well as a digital archive. 
I have created verification lists for clinical trials and clinical/observational studies, 
submission letters, site facilities declaration templates using the documents previously 
developed at CHCB as a basis. These documents are an attempt to harmonize the 
submission dossiers at Blueclinical’s network, and ease the work both from sponsors and 
Blueclinical staff. Verification lists summarize all the documentation necessary in the 
administration board submission dossier, and some specifications about them: mandatory 
content, availability of a hospital template, preferable language. Submission letters is one 
of the mandatory documents and it is supposed to be copied to the sponsor letterhead 
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paper. Its content includes a sum up of the project so that the administration board easily 
highlight the main aspects about the project. The site facilities declaration is a document 
completed by GAGIC in collaboration with the sponsor, regarding information about the 
conditions of the hospital facilities and the hospital staff available to perform the study. It 
is a statement about all the necessary facilities, equipment and staff, indicating whether it is 
provided by the hospital or by the sponsor.  
Using a Microsoft Excel® workbook, I developed a controlling tool to keep the stock of 
kits for blood samples collection controlled. The tool created has automatic forms in a way 
that the number of available kits and the next expiration date are highlighted. The necessity 
of such tool results of the fact that visit kits could be a critical issue when coordinating a 
clinical trial, as different visits mean different kits, and each kit means an expiration date. 
This document needs periodic updates, either when kits are used, or destroyed and when 
new kits are delivered at the centre. For each new trial an update to the document has to be 
done, creating a new page to that trial, and identifying each kit’s name. 
Another document I have created was the template to control patients’ expenses. Ethically, 
clinical trials’ participants cannot have expenses due to clinical trial’s procedures. 
Sponsors have the obligation of reimburse participants. On this document, besides 
information on the type, date and value of the expense, it is necessary the name of the 
study coordinator who received the expenses, the date when they are delivered to the 
clinical research associate (CRA), the CRA’s name, and the date when participant receives 
the money, and his/her signature. 
As GIC is part of the hospital structure, almost every day there is mail to be sent elsewhere 
inside the hospital. To keep a record of the sent mail and the date when it reaches its 
receiver, I have an internal mail protocol containing a sum up of what is being sent, the 
receiving date, and receiver’s signature. It is part of each letter/dossier/package sent, and 
must be returned to the office by the receiver. 
I have adapted the existent financial evaluation summary in order to make it easier to read. 
The objective of this document is to sum up the financial issues of a protocol and to ease 
the assessment performed by the administration board. This document contains 
information on study/trial name, sponsor, principal investigator (PI), beginning and ending 
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 date, number of patients, value per patient and total estimated value, percentage of the total 
value for the involved staff, for GAGIC and for the hospital as well as the  corresponding 
value. 
3.1.2. Feasibilities 
Feasibilities are questionnaires developed by sponsors to assess the potential of hospitals to 
develop a new protocol. Usually sponsors choose the investigators who they think are the 
most suitable to perform that protocol. When the sponsor does not have a specific 
investigator, the service director chooses one person of his/her medical staff to answer the 
questionnaire. Although there is not a model used to make the questionnaires, the majority 
of the approached topics are the same in every questionnaire. Usually feasibilities have 
questions about PI interests and experience, size and experience of the clinical staff, 
including study coordinators, characterization of the patients’ population and of the 
hospital facilities. 
During my stay at CHVNG/E, GAGIC coordinated the answer to 16 questionnaires from 
various sponsors. These contacts resulted in six clinical trials to be submitted or already 
submitted to administration board, eight clinical trials still waiting feedback from sponsor. 
Two of the clinical trials were cancelled. The target of these questionnaires were several 
clinical services as: haematology, pneumology, oncologic pneumology, rheumatology, 
paediatrics, gastroenterology, ophthalmology, neurology, nephrology and internal 
medicine. 
From the 16 questionnaires answered by GAGIC, I had the opportunity to answer one of 
them with a neurology physician. Before contacting the physician I made a selection of 
questions. Questions related with specific services from the hospital, as for example the 
pharmacy, were sent to that service, so the answers were the most accurate possible. Then I 
scheduled a meeting with the physician, where she answered questions about her team, 
experience and patient population. After that, I collected the answers of all services and 
submitted the questionnaire online. 
Some sponsors, after the submission of the feasibility, perform a qualification visit, to 
assess in loco the hospital facilities. I was present at one qualification visit in the 
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nephrology service. The visit began with the CRA explaining the protocol. After that the PI 
showed the facilities available to perform the trial. Issues like the possibility of performing 
the imaging exams requested by the protocol were discussed. Some documents, such as the 
Investigators Brochure acknowledge receipt, were signed. 
3.1.3. Investigators meeting 
I attended one Investigators’ meeting. This meeting occurred in Coimbra and counted with 
sponsor’s representatives and physicians from several hospitals where the clinical trial was 
going to begin soon. I was there as a CRC. The topics presented were: ICH-GCP; study 
drug pharmacological profile and clinical development; study protocol; Interactive Web 
Response System (IWRS); electronic case report form (e-CRF); AE and SAE reporting; 
tools for patients and investigators specific of the trial. Some issues such as ICH-GCP were 
briefly presented, and issues as the study protocol were presented in more detail causing 
discussion between sponsor and physicians, regarding the study procedures. 
3.1.4. Initiation meetings 
Initiation visits are the last step before the beginning of recruitment at a site. These visits 
are usually made by the CRA responsible for monitoring the clinical trial at the site. Ideally 
every team member should be present, so it is made an effort to schedule a time suitable 
for the majority of the staff. Normally, when this visit occurs, the study material is already 
at the site, as well as the study medication.  
This visit has two main objectives: giving training on the protocol to all the study staff and 
complete the delegation log. The delegation log is a document where everyone that takes 
part of the clinical trial staff is listed and their responsibilities are assigned. It also includes 
the date when the person becomes part of the staff and the date of exit, if it occurs prior to 
study termination. The PI must confirm the entrance and/or exit of every staff member, by 
dating and signing the log. 
I was present at three initiation visits, one at the dermatology service, one at the 
pneumology service and one at the immunoallergology service. At the dermatology 
meeting only the PI and the sub investigators were present, as this meeting regarded an 
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 observational study. At the other meetings, besides the PI and sub investigators, nurses and 
a pharmacist were also present. 
During these visits everyone received training on the protocol, credentials and explanations 
on IWRS and e-CRF systems, and the objectives of the clinical trials and 
inclusion/exclusion criteria were reviewed. Predicted timelines for milestones, such as half 
of the study population enrolled or end of enrolment were presented. At the dermatology 
meeting, as the service had little experience working with study coordinators, I explained 
which activities can be performed by the study coordinator, as for example fill in the CRF. 
During the visit, the medical staff identified the first patient to be included in the 
observational study. 
3.1.5. Patients recruitment 
The financial agreement signed between the sponsor and the hospital for every clinical trial 
or observational study establishes the number of patients to include in each study. For 
some studies it is possible to pre-screen patients, reviewing patients’ files, or patients’ 
databases, and when the enrolment period starts patients are included in the trial. This 
works for chronic diseases, like diabetes or chronic obstructive pulmonary disease. For 
diseases with faster development, like cancer, or for acute diseases, it is not possible to 
predict when there will be a patient to be enrolled. For these trials enrolment strategies 
have to be different. As I coordinated trials on lung cancer, the strategies I followed were 
attending at the weekly group meeting, distribute summary cards between the physicians 
and sometimes consult a database. During the group meetings physicians discuss the 
therapeutic alternatives for patients who were newly diagnosed with lung cancer or who 
had recently relapsed. My job was to evaluate if any of those patients fit the main inclusion 
criteria of the studies with open enrolment, or when physicians had doubts about the 
studies clarify them. Frequently it was hard to understand what physicians were saying, 
due to the specific terms used. I had the necessity to establish some key words that I can 
easily identify. If I heard one of those key words I had to find out if the patient being 
discussed fitted the inclusion criteria.  
I have done summary cards with the main specifications of the y, like, target disease, 
therapeutic line, experimental and reference drugs, and main inclusion criteria. The cards 
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were pocket size, so they fit the physicians’ lab coat pocket, and physicians can always be 
aware of the trials with open enrolment. For one or two times I had looked at the database 
with lung cancer patients, attempting to identify patients who could relapse and have 
criteria to enter the study. The search was done considering the diseases subtypes and the 
stages. 
Every time a patient was identified to enter a study, namely at the group meetings, I had to 
prepare the next consultation, moment when the physician presented the study and the 
informed consent form to the patient. For that visit I prepared a file with a checklist with 
all the procedures that have to be performed, the informed consent, a list of the 
inclusion/exclusion criteria, requisitions for imaging exams and a schedule for the next 
visits and treatments, if applicable. 
For the psoriasis study the patient was identified by the investigators team, who informed 
me during the initiation visit. When the patient visit was scheduled I was notified to 
prepare the necessary documents. 
3.1.6. Patients visits 
Before patient visits I performed several activities with the objective of simplify the visit, 
both on my perspective and the physician perspective. So, I prepared a worksheet that 
summarises the information that must be registered on the patient file, and identify 
important information that has to be followed up, like AEs and concomitant medication. 
To manage concomitant medication I used a worksheet where I registered every new 
medication and every update to the current medication, according with the information 
requested on the protocol. This worksheet depends on each protocol specification, but 
usually regards the medicine name, dosage, onset and offset date and therapeutic 
indication. I used a similar worksheet to manage AEs, requesting information like starting 
and ending date, relationship with study drug and grade. While preparing the next visit I 
checked on these worksheets the ongoing medication and AEs, and then made annotations 
on the physician worksheet so that he or she update the information. 
Another thing necessary to do is scheduling the following visits and imaging exams. These 
schedules were made according to the protocol and using a document with automatic fields 
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 that calculates the time frame for the visit or exam and the preferable date (Figure 11). In 
this document in accordance with the protocol I previously defined the timeframes for each 
treatment cycle and for each exam. When a patient was randomized I entered the 
randomization date in the appropriate cell and then automatically all the timeframes were 
displayed. Imaging exams were made at an external facility, so I did a phone call in order 
to schedule the exam and then sent the requisition by e-mail. I also wrote down the next 
important dates and gave them to the patient during the visit. 
 
Figure 11 – Exams and visits schedule tool. When entering the date of cycle 1 day 1 (randomization), every 
other date is displayed. 
On the day before the protocol visit, I left the physician worksheet and the medication 
prescription on the patient file. I also checked, near the nursing team, if the blood sample 
kit was prepared and if there was a questionnaire available to be given to the patient. 
On the visit day I attended the patient consultation, so I could help the physicians with any 
issues they had, mainly during the first visits or when the patients relapsed. After the 
physician evaluated the patient and decided that he/she was going to continue on the trial, I 
did the IWRS call. During this call a new medication kit was assigned to the patient. After 
that, I went to the pharmacy to pick up the medication and then I delivered it to the patient. 
Before or after the consultation, I tried to talk with patients, in order to know how they felt, 
give them the expenses money and receive the new expenses tickets. I also tried to ensure 
that they knew when the next appointment was and that they did not forget the dates. I also 
tried to make sure they did not forget to keep the medication packages and bring them on 
the follow visit. 
After the visit, on the same day, or on the following day, I had to fill in the CRF. Basically 
what I had to do was transcribing the information on the patient file to the sponsor e-CRF. 
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It was usual that during the visit, physicians forgot to write some details, as medication 
dosages, or AEs grades, that was mandatory information to full fill the e-CRF. So, on a 
post-it, I noted down the missing information and left it on the patient file. As soon as I had 
the opportunity, I contacted the physician in order to solve the pending issues. Although 
filling the e-CRF was a relatively simple task it took a considerable period of time. First of 
all, sometimes the necessary information was not completely available on the visit 
registries, mainly in the first visits, when demographic data and medical history was 
collected. So it was necessary to consult previous medical registries in order to find that 
information, and as a last resource contact the physician. Then, there were the e-CRF 
queries. There were three types of queries: automatic queries, data managers’ queries and 
CRAs’ queries. Automatic queries rised right after the introduction of data on the e-CRF. 
Usually regarded introduction errors (a comma used instead of a point, for example) or 
non-conformant data (for example, body temperature outside the frame defined per 
protocol). Normally these queries were easy to solve as it was only necessary to correct the 
wrong data or to confirm that the data available is correct. Data manager’s queries were 
usually more specific, as they were related with protocol procedures or safety data. These 
queries usually took longer to be solved as it was necessary to talk with the physicians to 
clarify them. CRA’s queries normally were raised after monitoring visits. They were about 
data not in accordance with the medical registries or missing data. 
Every time patients gave me their expenses, I copied them and send them by e-mail to the 
sponsor, in order to speed up the payment to the patient, which easily took longer than a 
month. When the sponsor’s representative gave me the money I gave it to the patient, as 
soon as possible. If the patient had left the trial, I called them, or any relative, if the patient 
died meanwhile, asking them to go to the site to receive the money. New strategies to 
simplify this procedure were discussed between GIC, sponsors and the hospital, being the 
transportation to the hospital provided by the sponsor one of the possibilities analysed. 
Some studies started to use this method. 
SAEs had to be reported to sponsor on the 24 hours after any element of the team 
acknowledge the event. The way SAE were reported depends on sponsors. Sometimes a 
SAE form was sent by fax and sometimes they were directly reported on the e-CRF. The 
initial report usually had few information, so it was mandatory to do follow-ups. After 
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 acknowledge the occurrence of a SAE and after identifying the way the report was done, I 
contacted the physician to fulfil the SAE form. After that, I submitted the form. In this 
initial report the information provided usually was the diagnostic, the initial therapeutic 
performed, the onset date and if there was any relation with the experimental drug. On the 
following days, I checked the patient file to get up-to-date information on the patient status 
and contacted directly the physician. When necessary, a follow up to the SAE was 
performed, updating the medication, laboratorial results and the outcome of the event. 
For observational studies no procedures outside the normal practice could be performed. 
So the checklists I developed were only used as a guidance to ask the physician if any of 
that information was available. After the visit I only had to fill in the e-CRF and if there 
was missing information I had to state on the e-CRF that these information was unknown. 
3.1.7. Monitoring visits 
Monitoring visits were a responsibility of the sponsor. During this visit, CRA performed 
source data verification, and checked the trial master file, for example. I had some tasks 
during these visits. I had to schedule the monitoring visits, regarding the PI and the CRA 
availability. I also had to make sure that the CRA had the necessary conditions to perform 
the visit – facilities, up-to-date e-CRF, and source data documentation available. Then, I 
had to correct all the mistakes identified by the CRA, for example correct a value wrongly 
entered on the e-CRF. When the issues identified had to be corrected in collaboration with 
the investigators, I must solve the issues with them at their earliest convenience.  
3.1.8. Other administrative tasks 
The trial master file (TMF) was a dossier with important documentation of the trial. It had 
to be kept up-to-date, and this is a responsibility of the site staff. The delegation log was 
part of the TMF documentation and was a document where all the site staff was listed and 
their responsibilities were assigned. For the trials I coordinated I was responsible to 
maintain this document, so every time someone left the team, he or she had to register the 
date they left and sign.  After that the document had to be signed by the PI. Other 
document present at the TMF was the Investigator Brochure and the protocol. When a new 
brochure or protocol was released I had to archive it and give the medical staff a document 
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where they stated that they have received the new version. The informed consent form was 
another document that could have new versions during the trial. In this case, I had to assure 
that every patient signed the new version of the informed consent form as soon as possible. 
Physicians had to explain the main changes on the informed consent, and the patients 
signed it if he or she wants to keep on the trial. The signature of the new informed consent 
form had to be documented on the patient file. One blank informed consent form had to be 
archived on the TMF and the old versions marked as outdated. 
Another responsibility I had at GAGIC was the payments control. On one hand, I 
maintained a document for each ongoing study, where all visits were registered as well as 
the value of each visit. On the other hand, I kept a document controlling the payments 
performed to the hospital, with the indication of the amount correspondent to GAGIC. The 
periodicity of payments was defined on the financial agreement between the hospital and 
the sponsor. When the sponsor pretended to pay to the hospital, the financial department 
was contacted in order to issue an invoice. After receiving the invoice, the sponsor 
performed the payment. It was internally defined that when the financial department 
received an invoice request, GAGIC was contacted by e-mail to inform if the values were 
correct. To check the values listed by the sponsor, I compared the sponsor request with the 
document where I controlled visits. Usually all the values were correct so I just had to 
inform the financial department of the division of the amount received. That amount was 
usually divided between the hospital, GAGIC and the clinical staff.  
As I had already stated, I created a document to control kits for blood samples stock. Using 
this document, at least once a month, I checked the stock and updated the document. If 
there were kits that had reached the expiration date, I destroyed them, saving the material 
that had no expiration date. If there was a small number of some type of kits, and I knew 
they would be needed soon, I requested them to the central lab, usually sending a request 
form with the amount of kits needed, by e-mail or by fax. 
As I was part of Blueclinical, I had some tasks that were a specific request of Blueclinical. 
The agreement between Blueclinical and the hospital established that a trimestral report 
had to be sent to the administration board. I developed that report twice. It was a sum up of 
all activities developed during the previous three months. The main objective of this report 
was letting the hospital administration board know which activities we had developed, and 
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 if the clinical research at the hospital was increasing or decreasing. Another task was the 
development of a database with all feasibilities answered, including the sponsor feedback, 
and all ongoing clinical trials, including information on number of recruited patients and 
value per patient.  
3.2. OTHER ACTIVITIES DEVELOPED 
As I said before, I left CHVNG/E in mid-January, and since then I spent some time at 
CHBV, CHTV and CHCB. At all the hospitals the activities performed by the CRC were 
more or less the same, so I kept on doing what I had learned at CHVNG/E, implementing 
some adaptations due to each hospital characteristics. 
At CHBV I was not responsible for any task as I spent little time there. I just followed the 
local CRC during her daily activities. I had the chance to learn how biological samples 
were processed, and sent to the central laboratory. I never had to process the biological 
samples, as at CHVNG/E it was a responsibility of the nursing team or of the local 
laboratory. Unlikely what I thought, the processing itself was a simple task as the 
laboratorial manual explained all the steps. After centrifugation, samples were placed on 
proper packing, so they could be sent to the central laboratory. 
During the days I spent at CHBV, I was alerted to some practices that are preferable to 
implement when the clinical research office only had one person. It was the case of 
preparing kits in advance, for example, at the end of one week prepare all the kits for the 
following week. A little more time could be wasted on that day, but while the patient was 
at the site, it was one less thing to do. 
At CHTV I had some new experiences. First of all, I had to make great pressure near the 
hospital administration board, in an attempt to solve all the pending issues which were 
disallowing the progression of the office activities.  
An important milestone was the first time the site was chosen to develop a clinical trial. I 
had to prepare the submission to competent authorities and to the hospital administration 
board. I contacted the PI and all involved services in order to complete the site facilities 
declaration. I needed information on characteristics and availability of the resources that 
would be used, and also information on the personnel that would constitute the trial staff. 
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At that time the close collaboration with other sites of the Blueclinical network was 
essential as I had never prepared a submission. All the documentation common to the all 
sites was only filled in once and then distributed between the Blueclinical offices. Due to 
this clinical trial, I was present at a two days Investigators’ Meeting at Barcelona. During 
the meeting, the study was discussed in detail as well as the protocol procedures and safety 
issues. As this was an international meeting, it was possible to share experiences between 
study sites. 
While at CHTV I started the distribution of the interest and capacities on clinical research 
questionnaire. It was a questionnaire developed by Blueclinical, with the intent of knowing 
which medical areas fitted the physicians’ interests, and also the physicians that intended to 
work with the clinical research office. This task allowed me to know many physicians in a 
short period of time. The first questionnaires were sent by e-mail after a meeting with some 
physicians. Although they provided their answer in a short period of time, I realized that 
this was not a good strategy as there are many services and I had not the chance to 
schedule all the meetings in the time frame I had to have an answer from every physician. 
Afterwards, I talked personally with all service directors asking them to collect the contact 
of all physicians and whether they prefer to have the questionnaire in paper or online. This 
strategy had a positive outcome as I was able to have sixty answers in only two weeks.  
One month after I started working at CHTV, as a consequence of a Blueclinical’s strategic 
decision I began working homebased, going to the hospital when it was necessary. 
Meanwhile I also had to go to CHCB on clinical trials visits days to support the local CRC. 
At CHCB, usually three or four patients were scheduled for the same day. Unlikely at 
CHVNG/E, I had to process the blood samples. For this process, the time of clotting of 
each tube and the centrifugation velocity had to be considered. It is also necessary to make 
sure that samples of each patient are not mixed up or contaminated. At this site it was 
necessary go to the pharmacy with patients so that the drug compliance was calculated, and 
if there was missing or extra tablets the patient can explain what happened. 
While I was home based I had a more theoretical job, as the tasks I did were translations, 
worksheets to clinical trials and review of standard operation procedures. All the projects I 
was involved at CHTV, like the submission procedure, and the interest and capacities on 
clinical research questionnaires were on hold.  
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 After a month working home based, and as there was no prevision of when the hospital is 
going to make a decision about the collaboration with Blueclinical, it was decided that I 
was moving to the Blueclinical back office where I could be more useful. So the last month 
of my curricular training was spent at the back office.  
Over there I did not have a project that was of my own responsibility.  The tasks I 
performed belonged to someone else project. I helped my colleagues with the creation of a 
tool to control the sponsors’ payments, the development of worksheets for different studies 
and the translation of some documents. The activity that differ the most of what I had 
previously done was the construction of a TMF. When I was at hospitals, the CRA delivers 
the TMF already completed during the initiation visit and I only had to keep it updated. To 
perform this tasks, first of all, and as for me it was a new task, I identified what are the 
documents necessary to each section. Then I requested them to my colleagues, and then 
archived them on the TMF. 
3.3. TRAINING 
Training is an essential part of the professional world. As a study coordinator training in 
protocols is mandatory, as well as in GCPs and in sample shipping. Training in protocols is 
provided by sponsors prior to the study initiation, or when the study is already ongoing, 
prior to the start of the collaboration, normally in person. At the end of each in person 
training session, I had signed a training log, where I confirmed I had been trained at the 
protocol. E-learning training usually regards the CRF and safety information and reports. 
At the end of the e-learning I habitually obtained a certificate that has to be sent to sponsor.  
Blueclinical provides training curricula to all its staff, regarding, for example, legislation 
and team building activities. Even before I started my training program, I was present at a 
training day at Blueclinical phase I headquarters. The meeting purpose was “Because 
People Matter: Building a Team!”, and it happed on the day of the first anniversary of 
Blueclinical. That was the first time I met with all Blueclinical staff, even though I already 
knew some people. During that day, we presented ourselves, learned about the Blueclinical 
History, Functional Areas, Values and Standards; Quality Management; Client Focus and 
Effective Communication. 
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At the beginning of September, Blueclinical team grown up, and four training days with all 
the Blueclinical business areas, were schedule. I missed the last day of training as I went to 
an investigators’ meeting. The training focused the legislation applicable to clinical trials 
and to the development of medical devices, data management, the stages that a clinical 
trials goes through at a site and the R&D process.  
In middle February there was another training meeting, this time only for the CRP staff. 
The objectives of the meeting were knowing the status of each office and identify 
strategies to solve troubles and improve the work being done. 
On the 1st of October I was present at a workshop about GCPs organized by University of 
Aveiro. At the workshop, GCPs were focused on a practical perspective, as real examples 
were given. 
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 4. DISCUSSION 
In this chapter I am going to describe how the activities I developed during my internship 
contributed both for my personal and professional growth, what were the major difficulties 
I have faced, as well as what were the major achievements. I will review the activities I 
had performed, regarding what I had learned while doing them, and how my academic 
background contributed to their realization. 
My internship was the first time ever I have contacted with the professional world. 
Although I theoretically knew that it is completely different from academia, the support of 
my colleagues and of the Blueclinical COD was essential to my adaptation. My academic 
background was a valuable tool during the internship even though it was always focused 
on a theoretical perspective of clinical trials. The knowledge on legislation, essential 
documents of a clinical trial, and product life cycle, allowed me to easily understand the 
reasons why some tasks are needed and to recognise the steps to perform next. In some 
situations the lack of a practical background was a disadvantage, making harder facing 
unexpected situations, for example. Other advantage of my academic background was the 
autonomy acquired with the problem based learning (PBL)2, as it makes students look for 
answers instead of teachers provide all the information. This method provided me skills on 
search and data presentation that were useful during my training. When I was asked to 
perform a new task, firstly I tried to understand what was being asked, what the purpose of 
the task was, and then how I could accomplish it. 
Time management was an important task, and maybe the one I have most improved during 
my internship. I learned that the first step is to calculate the time I expect to need to 
perform a task. Then, if I have more than one task to do at the same time, but I have no 
opportunity to do them all, I have to prioritize the tasks, doing first the one that is most 
important and most urgent. I did not feel that I needed a tool to help me prioritizing and 
estimating times, however I felt that a to-do list was essential. Now I have a calendar 
where I list every task I need to do and based on that, I, day by day, plan my activities. 
2 PBL is characterized by twice a week sessions, where during the first session a problem related with the course is presented and 
discussed, with participants having no or little knowledge on the subject. At the end of the session questions and learning objectives are 
defined. On the second session, after autonomous research work, the answers to the questions previously developed are presented. 
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Then, I learned that I had to have flexible timetables. On one hand, I have to adapt my 
timetables to the physicians’ availability. My regular working timetable was between 9 am 
until 18 pm, with an hour to lunch. Although if physicians only have free time outside that 
schedule I went to the hospital earlier in the morning or stayed after hours, or had a smaller 
lunch break. On the other hand, patients’ visits usually take longer than expected, so on 
visit mornings I did not plan to do any other tasks, even if there was only one patient. 
When visits had a duration minor than expected, I performed some of the pending tasks. 
Usually there were unexpected tasks, for instance physicians that needs help, the 
administration that asks for a new table, so, whenever it was possible, I tried to do every 
task not close to the deadline so I could managed unexpected situations. 
Another thing I have learned was to be more organized. My job involves a lot of paper, so I 
needed to be as organized as possible to keep every document up-to-date and not to lose 
any document. At the office I have created my own dossier where I archived every 
documents that I use to prepare the patients’ visits. All the important documents that were 
under my responsibility, were also archived on that dossier, until I had the chance to 
archive it on the right place or to give it to the intended person. All the documents I have 
created include the date of its creation in footnote, so it was possible to identify the 
versions of the document and assess if I was using the right version. When a new version 
of the study protocol was released I had to update my dossier, in order to be sure that I was 
using the most recent information available. 
Organization is also critical since I was responsible for more than one protocol. Every 
protocol has its own specifications, and I could not mix up the specifications of each 
protocol. As it was impossible to know every specification I had pocket size protocols that 
I carried for every visit so that I could clarify every doubt I or the physician had. 
Worksheets also had to have the study identified so I easily recognized them, and only use 
the right worksheet with the right patient. It was also essential to know which physician is 
assigned to each patient, so that issues related with subjects were only discussed with 
his/her physician. 
Also regarding organization, I created a secured document to store access information 
regarding the online pages of the studies. Each study has at least two websites that I need 
Page 38 of 47 
 
 to access frequently, and each website had different access credentials so I created that 
document to warrantee that I knew how to access all the websites.  
Developing templates made me think out of the box to achieve useful and easy-to-use 
documents. Some templates, such as the concomitant medication worksheet, were the 
result of difficulties I felt. In the case of concomitant medication, I had patients that have 
more than 10 different drugs every day, and the physician usually forget to write down 
some of those drugs, so I need a tool that allows having medication under control and 
knowing exact information about it, such as the onset and offset date.´ 
At the beginning of my internship, reading and understanding study protocols was 
sometimes difficult, due to the language used. Also, the protocol organization depends on 
the sponsor. With training, it was possible to easily recognise which is the section where 
the information I was looking for is. 
As a CRC, I had to contact with several people – study teams, sponsor’s representatives, 
patients, patient’s relatives. Due to this I had to overcome the lack of self-confidence and 
the stress I felt when I had to talk with other people. At CHTV I had a few stressful 
situations, as I had to face negative opinions about the clinical research office (at 
CHVNG/E it was the clinical research manager that faced those opinions, so I never had to 
directly deal with them). Those were challenging situations, that made me realized that I 
had a lot to improve regarding the opinions of other people. Since then, in similar 
situations, I try to better evaluate what is being said and use better arguments to support 
my point of view. 
Talking to patients was also challenging. On one hand medical issues had to be discussed 
with physicians and it was not my job to talk about them with patients or their relatives. 
Although patients frequently asked me questions that lead to medical issues so I had to tell 
them to talk directly with the physicians. Patients could misunderstand anything I said so I 
had to be really careful while choosing the words I was going to use. 
Patients participating in clinical trials have to go frequently to the hospital, sometimes 
more than once a month. I accompanied them at every visit, trying to make their 
experience at the hospital easier. Following patients, made me aware of their health status, 
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and sometimes I knew before them that they were relapsing, or that the tumour was getting 
smaller, for instance. During my internship, the health status of the patient, to whom I first 
prepared the screening and randomization visits all by myself, quickly deteriorated, and the 
patient died only a few months after randomization. This had affected me as I was not 
prepared to face death. I understood that I needed to improve the way I interacted with 
patients, keeping a distant relationship with them, so that, in future I would not be so 
affected by their health or death. I do not exactly know how to improve this aspect, as I 
think that gaining more experience is the best way to progress. Even though, taking part of 
workshops regarding how to behave with patients is an option that I will take in 
consideration in short term. 
As far as GCP’s compliance is concerned, I felt some difficulties. Physicians knew what 
GCP’s are and knew that they have to conduct clinical trials in compliance with GCP’s and 
protocols, nevertheless it was hard to make them perform tasks according with GCP’s. For 
example, GCP’s stated that when a mistake is done in a handwritten paper it could be 
solved by crossing the wrong information out, write the right one, sign and date. 
Physicians never remember to sign and date and usually scratch the wrong information, not 
allowing it to be read. Another problem was the AEs. Some physicians do not understand 
that every AE is important, even if it is not related with the experimental product. I could 
only overcome these problems with persistence, and patience. It was interesting to observe 
how some physicians, as the time went by, became more aware of what they needed to do, 
to follow the protocol and GCP’s. Understanding physicians’ hand-write was challenging. 
Only practice, and reading the patient files every week allowed me to be more expedite 
understanding the abbreviations used and the calligraphy. 
Regarding my training objectives, I have not achieved all of them. The objectives that are 
not related with the company were, in my opinion, achieved. Now I have a more fluent 
speech, both in English and in Portuguese, and I am able to organize my ideas before 
starting to speak. My written skills improved, as now I am more precise and brief. As 
described above, I used the knowledge acquired in my degrees in various situations. 
Through my training I realized I was becoming more autonomous, and organized. My self-
confidence has increased, although I did not always felt confident. My team group working 
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 skills have improved, and being part of Blueclinical was a great influence in this aspect, as 
the company boost team work. 
Contacting with different CRA’s allowed me to develop my professional network and also 
know some information about other pharmaceutical companies. 
During my training I have understood what the steps to implement a clinical research 
office were, and how difficult this task could be, as it depends on many people, that not 
always agree with the project or that simply do not care about it. It is necessary to be 
persistent and not let that issues are forgotten. 
I was also able to know how to plan, conduct and coordinate a clinical trial and an 
observational study, excluding the close-out visits. I participated in every step since the 
submission preparation until the patients’ visits. The submission tasks were the tasks I 
contacted less with, although I think I will be comfortable performing a submission 
whenever necessary. Patients’ visits were, without doubt, the task where I gained more 
experience. During my training I worked mainly with protocols on cancer, and I believe 
that was an advantage, as these protocols usually are the more complex ones. 
I think I have acquired basic knowledge in monitoring tasks, as I was present in various 
monitoring visits, and some of the CRA’s have shared their experience. I do not feel I have 
the necessary knowledge to perform a monitoring visit, although now I know that a 
monitoring visit could regard for example source documents verification and medication 
reconciliation. At the end of the visit a monitoring report has to be developed and the 
protocol deviations, corrective actions and pending issues communicated to the site. 
I developed a good relationship with the physicians and other clinical trial personnel I 
worked with, although I do not know if I increased their motivation to perform clinical 
trials. There were moments where I felt that they were motivated and liked to do research, 
when for example they not only signed a document but also asked information regarding 
the study. Nonetheless, there were other moments when it seemed as they prefer not to 
participate in clinical trials. This happened when they, for instance, transformed a small 
problem into a big one. On the other hand, I felt that I positively influenced some elements 
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of the staff to be GCP compliant. I believe that both the motivation and the GCP 
compliance are factors that have to be worked every day, and changes happen slowly. 
As far as the relationship with the Blueclinical staff is concerned, I believe I fully achieved 
the proposed objective as I have a positive relation with all of my colleagues. I established 
closer contact with the CRP staff, even though each of us is based at a different hospital. 
Digital tools, such as e-mail and instant messaging services are frequently used to keep in 
contact and to ask for clarifications or help. 
I failed to achieve the objective about inspections and audits and the one about financial 
agreements. As none of the clinical trials I coordinated was submitted to an inspection or 
audit I had not prepared the site to these activities. However I have realized that preparing 
a site for an audit/inspection is an ongoing job, as it is necessary to do our best, minimize 
mistakes and protocol deviations and implement corrective and preventive actions, every 
day. Studying protocols and creating worksheets were tools I used as an attempt to reduce 
mistakes. 
During my internship I was not focused on the submission process, so I did not had the 
opportunity to review and improve the financial agreements between sponsors and 
hospitals. Although I learned that the financial agreement must include information about 
the payment of patients’ expenses and of unscheduled visits. Regarding the patients’ 
expenses, the value defined must be in accordance with the influence area of the hospital, 
as a patient could not be penalized for living far away from the hospital. 
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 5. CONCLUSION 
Overall, thinking about what I have done, learned and experienced during my internship I 
have to assume that it was more than I have ever imagined. I am sure I had developed 
several skills, both hard and soft skills, which will be very valuable during my career. 
Almost every day I had to interact with someone I had never met before, or to perform a 
new task, or to solve an unexpected issue. Not knowing exactly how the following day 
would be, what challenges I would have to face next, was a positive aspect of my training. 
The pharmaceutical industry has been affected by the present economic crisis, and is facing 
changes in the R&D paradigms. Being able to adapt to different work environments will be 
a key characteristic for everyone working in this area. I think that during my training I 
started developing these characteristics as in a short period of time I was present at 
different institutions, each one with its own peculiarities. 
During these ten months I had the opportunity to contact with the professional world, know 
the realities of different hospitals, and also the reality of working at an office. All the 
difficulties I faced were overcome with hard working and with the support of my 
colleagues. I still do not feel ready to survive in the professional world, but the experience 
acquired during this period has an incalculable value to my future, and used in the right 
way will allow me to have a successful career. 
My internship was a remarkable period and overall the majority of my objectives were 
accomplished, however not always fully accomplished. I still have a long learning journey, 
and both my hard and soft skills have much to improve. 
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